Key result
Half-dose heparin flush during IABP support linked to ~85% lower clinically significant bleeding vs standard-dose.
Why the study?
Whether a half-dose heparin flush strategy during IABP support improves safety compared with a standard-dose strategy in patients with CS needed evaluation.
Does a half-dose heparin flush strategy reduce clinically relevant bleeding and thrombocytopenia compared with a standard-dose strategy in patients with cardiogenic shock receiving intra-aortic balloon pump support?
Cohort (n=128)
No
Does a half-dose heparin flush strategy reduce clinically relevant bleeding and thrombocytopenia compared with a standard-dose strategy in patients with cardiogenic shock receiving intra-aortic balloon pump support?
In cardiogenic shock patients supported by an IABP, a half-dose heparin flush strategy significantly reduces clinically relevant bleeding, thrombocytopenia, and transfusion requirements without increasing thrombotic or occlusion events.
Answers are grounded in this paper and cite their sources.
Should not yet alter IABP anticoagulation protocols; hypothesis-generating for randomized trials to confirm bleeding reduction.
The study aimed to evaluate whether a half-dose heparin flush strategy during intra-aortic balloon pump (IABP) support improves safety compared with the standard-dose strategy in patients with cardiogenic shock (CS). In this single-center retrospective cohort study, 128 CS patients who received IABP support between January 2023 and December 2024 were included. Sixty-eight patients received a standard-dose heparin flush, and 60 received a half-dose flush. The primary endpoints were clinically relevant bleeding (Bleeding Academic Research Consortium 2, 3, or 5) and thrombocytopenia (platelet count < 100 × 10 9 /L). Multivariable logistic regression was conducted, adjusting for dual antiplatelet therapy and renal dysfunction. The incidence of clinically significant bleeding events and thrombocytopenia was significantly lower in the half-dose group than in the standard-dose group ( P < .05). Compared with the standard-dose group, the half-dose heparin flush strategy was significantly associated with a lower risk of clinically significant bleeding (odds ratio = 0.15; 95% confidence interval = 0.03–0.68). Among the secondary outcomes, the half-dose group had a significantly lower transfusion requirement than the standard-dose group ( P < .001). No significant differences were observed between the 2 groups in activated partial thromboplastin time, activated clotting time, in-hospital mortality, or catheter-related occlusion events. In patients with CS receiving IABP support, the half-dose heparin flush strategy was associated with lower incidences of thrombocytopenia, clinical bleeding, and transfusion requirements. No device-related thrombotic events were observed in either group, suggesting that the half-dose heparin flush strategy may contribute to optimizing anticoagulation management during the peri-support period.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a cohort in Cardiogenic shock supported by intra-aortic balloon pump (IABP) (n=128). Half-dose heparin flush strategy vs. Standard-dose heparin flush strategy was evaluated on Clinically relevant bleeding (BARC 2, 3, or 5) and thrombocytopenia (platelet count < 100 x 10^9/L) (OR 0.15, 95% CI 0.03-0.68, p=<0.05). A half-dose heparin flush strategy during IABP support was associated with lower clinically significant bleeding vs standard-dose (OR 0.15; 95% CI 0.03-0.68; P<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: